×![]()
Conference Buzz
Top Themes at EHA 2026
Most-discussed scientific topics across 851 curated tweets from 260 hematologists and researchers. Tap any card to see the tweets.
63
CAR-T & Cell Therapy
30.8K impressions
tap to see tweets
49
MPN / Myelofibrosis
18.8K impressions
tap to see tweets
38
Venetoclax Combinations
16.0K impressions
tap to see tweets
32
MRD Monitoring
11.4K impressions
tap to see tweets
26
BCMA & Myeloma Bispecifics
31.0K impressions
tap to see tweets
24
Transplant & GvHD
7.6K impressions
tap to see tweets
23
Menin Inhibitors (AML)
12.0K impressions
tap to see tweets
19
MDS & Anemia
8.6K impressions
tap to see tweets
17
BTK Inhibitors & Degraders
4.7K impressions
tap to see tweets
14
CD20 Bispecifics
8.7K impressions
tap to see tweets
9
Gene Therapy & Sickle Cell
12.2K impressions
tap to see tweets
Editor’s Picks
Key Tweets from the Floor
Hand-picked slides and standout posts curated by the KOL Pulse team from the EHA 2026 floor. Click any image to expand.
Benlazar S M A @smbenlazar
Joaquín Díaz-Schmidt @iHematologo
Benlazar S M A @smbenlazar
Benlazar S M A @smbenlazar
Rahul Banerjee, MD, FACP @RahulBanerjeeMD
Ahmed Kotb @AhmedKo45911157
Benlazar S M A @smbenlazar
Mike Thompson, MD, PhD, FASCO @mtmdphd
Mike Thompson, MD, PhD, FASCO @mtmdphd
Mike Thompson, MD, PhD, FASCO @mtmdphd
Rahul Banerjee, MD, FACP @RahulBanerjeeMD
Ahmed Kotb @AhmedKo45911157
Benlazar S M A @smbenlazar
Ahmed Kotb @AhmedKo45911157
Mike Thompson, MD, PhD, FASCO @mtmdphd
Raul Cordoba, MD, PhD #EHA2026 @DrRaulCordoba
Ahmed Kotb @AhmedKo45911157
Mike Thompson, MD, PhD, FASCO @mtmdphd
Raul Cordoba, MD, PhD #EHA2026 @DrRaulCordoba
Mike Thompson, MD, PhD, FASCO @mtmdphdLeaderboard
Top Voices by Impressions
Ranked by total impressions across all EHA 2026 tweets captured. Switch tabs to view physicians, institutions, and media separately.
Top Tweets & Trials
Top Tweets by Disease Area
Highest-impact physician tweets by blood cancer subtype. Expand the Clinical Trials section under each disease area to drill into trial-specific discussion.
Multiple Myeloma96 tweets captured
TECLISTAMAB IMPROVES DEPTH OF RESPONSE AND PFS VERSUS LENALIDOMIDE-DEXAMETHASONE IN HIGH-RISK SMOLDERING MULTIPLE MYELOMA https://t.co/kcMXGzYpiJ #mmsm #EHA26 https://t.co/DNFDW7wX0G
👁 11.5K
❤ 27
🔁 10
4) LINKER-AL2: Linvoseltamab in relapsed AL amyloidosis. (Wechalekar, Lee, 7502)
BCMA bispecifics are like magic in this population.
In 20 pts:
✅ No DLTs or ICANS
✅ CRS/IRR were Grade 1–2, mostly during step-up dosing
✅ heme OR: 100% with 80 mg; 92% with 240 mg
✅ Median time
👁 4.5K
❤ 15
🔁 3
Excited to be headed to Stockholm for #IMFIMWG26 and #EHA2026
As the 🇸🇪 song goes,
🎶 Gimme gimme gimme a cure after midnight!
The late-night discussions here will shape how we make myeloma curable across the 🌎 at first line… lots of work to do, but we are getting closer! https://t.co/pkLNfJDXOK
👁 3.4K
❤ 39
🔁 4
I am blown away every time I see the amazing PFS estimates (>17yrs in PERSEUS) in the era of anti-CD38 quads upfront in NDMM. #EHA26 #EHA2026 #mmsm https://t.co/aQOsVwghfg
👁 1.5K
❤ 20
🔁 10
🔹 Is There Still a Place for Mezigdomide in the Modern Myeloma Treatment Landscape?
Let’s see what data we have before we jump to conclusions?
🧵 ASCO 2026 | SUCCESSOR-2: Mezigdomide + Kd :
1/🔬 let’s start with the study Design (very Critical)
SUCCESSOR-2 randomized RRMM https://t.co/fuF6cXsdc6
👁 1.1K
❤ 17
🔁 7
Made it! …. And I have a room with a view. #EHA26 #EHA2026 #mmsm #myeloma https://t.co/AcuGVKaf1Z
👁 1.0K
❤ 20
🔁 1
Clinical Trials12 trials with discussion
Immuno-PRISM
Teclistamab vs Len-Dex · high-risk smoldering MM (EHA-7181)
▼
MajesTEC-3
Teclistamab + Daratumumab · R/R MM
▼
TECLISTAMAB PLUS DARATUMUMAB (TEC-DARA) IN PATIENTS (PTS) WITH RELAPSED REFRACTORY MULTIPLE MYELOMA (RRMM): ANALYSIS OF MAJESTEC-3 BASED ON CYTOGENETIC AND FUNCTIONAL RISK https://t.co/MCb33znS4i #mmsm #EHA26 https://t.co/PB0FaSBHph
👁 4.3K
❤ 34
🔁 14
🇸🇪 There are hundreds of abstracts at #EHA2026.
You cannot read them all.
For myeloma & cellular therapy only, I grouped the meeting into 5 buckets:
🏆 Practice-changing
🚀 Breakthroughs
⏳ Mature data
🧬 Novel biology
🌱 Future horizons
My top sessions include MAJESTEC-3, https://t.co/et8BsQaPm9
👁 866
❤ 19
🔁 7
CONGRESS | #EHA2026 | POSTER
Joshua Richter presents findings from a matching-adjusted indirect comparison of belantamab mafodotin plus bortezomib and dexamethasone (BVd; ESS = 47) vs teclistamab plus daratumumab (Tec-Dara; n = 291) for the treatment of RRMM.
Following https://t.co/wCI0jDK287
👁 170
❤ 3
🔁 1
LINKER-AL2
Linvoseltamab monotherapy · R/R AL amyloidosis (S208)
▼
4) LINKER-AL2: Linvoseltamab in relapsed AL amyloidosis. (Wechalekar, Lee, 7502)
BCMA bispecifics are like magic in this population.
In 20 pts:
✅ No DLTs or ICANS
✅ CRS/IRR were Grade 1–2, mostly during step-up dosing
✅ heme OR: 100% with 80 mg; 92% with 240 mg
✅ Median time
👁 4.5K
❤ 15
🔁 3
🧬 BCMA-directed therapy may be entering a new disease space.
Early results from LINKER-AL2 suggest linvoseltamab can produce rapid and deep hematologic responses in relapsed/refractory AL amyloidosis—even after prior daratumumab exposure.
Key question remains:
Will light-chain https://t.co/B0tJnQILlN
👁 266
❤ 1
🔁 0
SUCCESSOR-2
Mezigdomide + Kd vs Kd · RRMM (LB5004, P3)
▼
Mezigdomide moves to Phase 3 success in early relapsed myeloma.
The phase 3 SUCCESSOR-2 trial met its primary endpoint, showing that mezigdomide + carfilzomib/dexamethasone (MeziKd) significantly improved outcomes versus Kd alone in patients with relapsed/refractory multiple
👁 828
❤ 6
🔁 3
@MyelomaOslo revisiting SUCCESSOR-2 data here at #EHA26 #EHA2026 this morning. Interesting positive signal in hard-to-treat EMD. #mmsm https://t.co/dff1raYMoi
👁 582
❤ 8
🔁 3
🔴 Multiple Myeloma: SUCCESSOR-2 — mezigdomide + Kd in anti-CD38/IMiD-exposed RRMM — reports ORR >80% with deep responses.
If confirmed, this may significantly redefine salvage therapy sequencing.
👁 130
❤ 1
🔁 0
🚨 Latest #Oncology Update!
🔷 The Phase III SUCCESSOR-2 trial showed that Mezigdomide + Carfilzomib + Dexamethasone (MeziKd) significantly improved outcomes in relapsed/refractory multiple myeloma, reducing the risk of disease progression or death by 52% versus Carfilzomib + https://t.co/RIjwYRoYS9
👁 99
❤ 0
🔁 0
PERSEUS
Dara-VRd · transplant-eligible NDMM
▼
inMMyCAR
KLN-1010 in vivo CAR-T (no lymphodepletion) · R/R MM (FIH Ph1)
▼
👏Fascinating talk by Professor Andrew Spencer from Australia 🇦🇺 at #EHA26 #EHA2026 on #InVivoCART #inMMyCAR first-in-human ph1 KLN-1010 for patients R/R MM #mmsm https://t.co/shmqL8qaXP
👁 521
❤ 16
🔁 6
Revisiting here at #EHA26 #EHA2026 the KLN-1010 inMMyCAR in vivo CAR (no lymphodepletion needed). Looking good so far. 100% MRD negative responses, all CRSs where grade I-II (one ICANS grade 3), cytopenias and infections notably limited. Also good to hear the subject who https://t.co/VPBOzcDldZ
👁 414
❤ 11
🔁 9
🚨 Breakthrough in #MultipleMyeloma treatment: KLN-1010, an in vivo anti-BCMA CAR T therapy, achieves 100% MRD negativity in relapsed/refractory patients, with some remaining progression free beyond 9 months. 🔬 #EHA2026
Read the full data 👉 https://t.co/tXcyzOBkXa
👁 85
❤ 0
🔁 0
🇦🇺 Andrew Spencer presents update of KLN-1010 in vivo BCMA CAR-T #EHA2026
N=18
Median prior lines 3.5. 56% TC refractory.
Median time consent to infusion 13d.
Median FU 2.8m
100% MRD neg. 1 early PD & 1 early MRD resurgence.
No grade 3 CRS. 1 grade 3 ICANS.
Cytopenias short lived https://t.co/Rr5JUxIkCk
👁 72
❤ 0
🔁 0
MonumenTAL-3
Talquetamab + Dara +/- Pom · R/R MM
▼
DURGA-1
AZD0120 CD19/BCMA dual-targeting CAR-T · R/R MM (Ph1b/2)
▼
@bhemato updating here at #EHA26 #EHA2026 AZD0120 DURGA-1 FasTCAR study #mmsm https://t.co/txVQeWvCOf
👁 285
❤ 11
🔁 6
👏👏👏 #AZD0120 : a novel #CD19/#BCMA dual CAR-T for R/R MM |||| #DURGA-1 | Congrats to Dr @bhemato on his outstanding presentation at #EHA26 #EHA2026 !!!! #mmsm @EHA_Hematology | n=27 | @ninashah33 @DrKrinaPatel @MalinHultcrantz https://t.co/Kr4cnFLSSz
👁 273
❤ 8
🔁 3
#EHA2026 @bhemato presents updated data from DURGA-1
Phase 1b/2 AZD0120 - CD19/BCMA dual targeting CAR-T
ORR 100%, early MRD neg in 95% ev. pts
No grade 3 CRS
1 grade 1 ICANS
Grade 3+ infections 7.4%
Median time apheresis to infusion 14d
DURGA-4 open at St Vincent’s, Sydney https://t.co/ttQ86F3vUG
👁 71
❤ 0
🔁 0
ERASMM (EMN34)
Elranatamab · early intervention high-risk smoldering MM (S205)
▼
#EHA2026 one of the biggest takeaways of any SMM trial is the importance of ruling out active MM to avoid undertreatment.
#cyrilletouzeau presenting ERASMM now. Of 76 screened patients, 16 actually had active MM lesion on PET or MRI.
Make sure you rule out active myeloma! https://t.co/AlgfDOSm7Y
👁 187
❤ 4
🔁 2
CONGRESS | #EHA2026 | PRESENTATION
Cyrille Touzeau presents first results from the phase II ERASMM study evaluating elranatamab administered for a fixed duration of 2 years as an early intervention strategy in high-risk smoldering multiple myeloma (n = 50).
At a median FU of 14 https://t.co/rtET6Pe9ff
👁 95
❤ 1
🔁 0
(S205) Promising results from the ERASMM (EMN34) study on Elranatamab for High-Risk Smoldering Myeloma (HR SMM)
✅ ORR: 92%
✅ ≥CR: 45%
✅ 9-month PFS: 95%
Early intervention with T-cell engagers shows robust efficacy and a manageable safety profile.
#EHA2026 #mmsm
👁 78
❤ 1
🔁 0
AGMT-MM04
Isa-Rd -> Isa-R maint. vs Rd -> R maint. · elderly NDMM (PF766)
▼
CEPHEUS
Dara-VRd · transplant-ineligible NDMM
▼
CARTITUDE-4
Cilta-cel · lenalidomide-refractory MM
▼
Lymphoma120 tweets captured
HIGH-DOSE METHOTREXATE DOES NOT REDUCE RISK OF CNS RELAPSE IN ULTRA HIGH-RISK LARGE B-CELL LYMPHOMA https://t.co/SoGvtevT48 #EHA26 https://t.co/8mNkeSY1xY
👁 14.6K
❤ 58
🔁 18
POLA-R-ICE vs R-ICE in r/r LBCL
Adding pola to R-ICE missed its 1ary endpoint overall.
Subgroup winners: DLBCL, relapsed, bulky disease & ⬆️ LDH all showed meaningful OS benefit.
1ary refractory disease? Pola won't save it. Perhaps BsAb-chemo combos are the answer there? #EHA2026
👁 12.5K
❤ 48
🔁 9
frontMIND: a new first-line regimen for high-risk DLBCL?
The phase III frontMIND trial (Lenz et al., Lancet) adds tafasitamab (an Fc-enhanced anti-CD19 antibody) + lenalidomide to R-CHOP, in 899 patients with high-intermediate or high-risk DLBCL/HGBL (IPI 3-5 or aaIPI 2-3).
The
👁 9.6K
❤ 27
🔁 8
Will you stop giving CNS prophylaxis for testicular lymphoma after #EHA2026?
👁 6.6K
❤ 2
🔁 1
A compilation of top lymphoma/CLL abstracts from #EHA2026 by @lymphomahub steering committee.
Looking forward to some great data.
@chanyooncheah @Dr_KatLewis @tobyeyre82 @WomenInLymphoma @KrishPatelMD @elizabeth_budde @StefanoLuminari https://t.co/LTLOisPbJa
👁 2.2K
❤ 17
🔁 6
‼️ #EHA2026 simultaneous publication by @mattwilson2287 et al:
High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Analysis of 1,923 Patients
Read the full article: https://t.co/s7pXBU1vVc https://t.co/TkNPSzelOJ
👁 1.6K
❤ 6
🔁 9
Clinical Trials10 trials with discussion
Pola-R-ICE
Polatuzumab + R-ICE vs R-ICE · 2L LBCL (Ph3, S237)
▼
frontMIND
Tafasitamab + Len + R-CHOP · newly diagnosed DLBCL (Ph3, S101)
▼
frontMIND: a new first-line regimen for high-risk DLBCL?
The phase III frontMIND trial (Lenz et al., Lancet) adds tafasitamab (an Fc-enhanced anti-CD19 antibody) + lenalidomide to R-CHOP, in 899 patients with high-intermediate or high-risk DLBCL/HGBL (IPI 3-5 or aaIPI 2-3).
The
👁 9.6K
❤ 27
🔁 8
WATCH: @SoniSmithMD of @UChicagoHemOnc shares implications of data from the phase 3 frontMIND trial evaluating frontline tafasitamab plus lenalidomide/R-CHOP in high-risk DLBCL #lymsm #oncology https://t.co/SGlKlHKrWZ
👁 445
❤ 3
🔁 1
frontMIND Ph3 in newly diagnosed high risk LBCL
First data presented #ASCO26 by DrGeorgLenz 🇩🇪 with simultaneous publication @TheLancet
Look out for plenary at #EHA2026
https://t.co/SOnRrDVahJ
👁 311
❤ 4
🔁 0
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25%… https://t.co/vzHVOWiF5K #Tafasitamab #Monjuvi #DLBCL #CancerResearch #ClinicalTrials
👁 137
❤ 1
🔁 0
🚨 Latest #Oncology Update
🔷 Incyte’s pivotal frontMIND trial demonstrated that a Tafasitamab (Monjuvi®/Minjuvi®)-based combination significantly prolonged progression-free survival in patients with previously untreated, high-risk diffuse large B-cell lymphoma (DLBCL). The https://t.co/2g842QtqMb
👁 106
❤ 0
🔁 0
Lymphoma - New Agents - DLBCL - Lenz - #EHA2026 #lymsm #caxtx frontMIND #NCT04824092 https://t.co/0JSttNZctW
👁 68
❤ 0
🔁 0
#frontMIND: tafasitamab + lenalidomide + R-CHOP reduced the risk of progression/death by 25% in frontline high-risk DLBCL/HGBL.
👁 66
❤ 0
🔁 0
EPCORE NHL-1
Epcoritamab monotherapy · R/R LBCL (PF977)
▼
EPCORE DLBCL-1
Epcoritamab vs chemo-IO · R/R LBCL (Ph3, S235)
▼
LB2501 (CAR-T)
In vivo CD19/CD20 dual CAR-T · R/R B-NHL
▼
FIRST-IN-HUMAN TRIAL OF LB2501, AN IN VIVO CD19/CD20 DUAL TARGETING CAR-T THERAPY, IN RELAPSED/REFRACTORY B-CELL NHL https://t.co/NzJceo5qcL #EHA26 #lymsm https://t.co/GlIXS1tmKw
👁 1.0K
❤ 5
🔁 4
China contributes 2 of the 9 LBAs selected for #EHA2026: Hu & Mei et al.'s BCMA CAR-T for refractory ITP and Fan et al.'s first-in-human in vivo CD19/CD20 dual-target CAR-T (LB2501) for R/R B-NHL. Looking forward to EHA!
👁 83
❤ 2
🔁 0
Legend Biotech’s LB2501 may become one of the most important in vivo CAR-T stories at #EHA2026.
CD19/CD20 dual-targeting in vivo CAR-T
DL2 cohort: ORR 100%（6/6）, CR 83.3%（5/6）
No DLT, SAE or ICANS reported in preliminary data https://t.co/oZku7CGv9w
👁 5
❤ 1
🔁 0
HD21
PET-guided BrECADD · older advanced cHL (S221)
▼
FINAL ANALYSIS OF THE GHSG HD21 OLDER COHORT: EFFICACY, SURVIVAL AND LATE TOXICITY OF PET-GUIDED BRECADD IN OLDER PATIENTS WITH ADVANCED-STAGE CLASSIC HODGKIN LYMPHOMA https://t.co/d0n3aoagRD #lymsm #EHA26 https://t.co/JqMrTJYT67
👁 594
❤ 4
🔁 1
Lymphoma - New Agents - BrECADD in cHL young. #EHA2026 #lymsm #caxtx https://t.co/rCVA4Z8NRS
👁 71
❤ 0
🔁 0
STARGLO
Glofitamab + GemOx · R/R DLBCL
▼
#EHA2026 PF1061 TMTV as a early progressive factor in RR DLBCL: results from
STARGLO trial #lymsm https://t.co/6sJpBcroTB
👁 275
❤ 3
🔁 0
🩸#EHA2026 2L DLBCL Beyond CAR-T
📌For patients not eligible for or not proceeding to CAR-T or ASCT, Glofitamab-GemOx (Glofit-GemOx) is now a recommended second-line option in EHA guidelines
💡 Bispecific antibodies are rapidly reshaping the treatment landscape of relapsed/ref. https://t.co/FduYdhIQsT
👁 241
❤ 8
🔁 2
EPCORE FL-1
Epcoritamab + Len + Rituximab · R/R follicular lymphoma (Ph3, S229)
▼
EPCORE FL-1 showed that epcoritamab/lenalidomide/rituximab yielded superior efficacy vs lenalidomide/rituximab across follicular lymphoma populations. @EHA_Hematology #EHA2026 #lymsm #hematology
https://t.co/YphHQHTdBd
👁 366
❤ 1
🔁 0
CONGRESS | #EHA2026 | PRESENTATION
Benoit Tessoulin presents results from an analysis of clinically relevant subgroups from the phase III EPCORE FL-1 trial, assessing the efficacy and safety of epcoritamab in combination with lenalidomide + rituximab (R2) vs R2 in patients with https://t.co/lQT68wjoGS
👁 132
❤ 3
🔁 0
POLAR BEAR
R-Pola-mini-CHP vs R-mini-CHOP · elderly/frail DLBCL (S238)
▼
SUNMO
Mosunetuzumab + Pola vs R-GemOx · R/R LBCL (Ph3, PF968)
▼
Leukemia (AML · ALL · CLL · CML)233 tweets captured
🚨 breaking news from #EHA2026 GILTERITINIB did NOT improve OS over MIDOSTAURIN IN 760-patient randomized phase 3 trial of their combinations with intensive chemo for newly diagnosed FLT3Mut #AMLsm trial
EHA Library; Jun 02 2026; 4214972
https://t.co/jSa9RgSKue
👁 6.5K
❤ 88
🔁 25
I believe I'll keep doing HD-MTX even after #EHA2026.
Old habits die hard. Eager to see all data to help me change practice. https://t.co/kya1IZ1tiu
👁 5.9K
❤ 14
🔁 0
Excited to head to #EHA2026 where I will present results of the much anticipated OPTI-AML study on behalf of the BEAT AML investigators @bcutd_research Master Trial ,Thurs Jun 11-see details 👇🏾. Hope to see many of you there ! In the words of ABBA seeing as we are in Stockholm. https://t.co/si0GNJ6Ict
👁 4.9K
❤ 67
🔁 10
#EHA2026 EHA Guidelines on management of chronic lymphocytic
leukemia and Richter transformation @Hemasphere_EHA
https://t.co/S3IztQMdu9
#lymsm #leusm #hematology https://t.co/xwj1CzSe7O
👁 2.8K
❤ 66
🔁 20
#EHA2026 LBA
Primary results of BRUIN CLL322
FD Pirto-VenR vs VenR
80% cBTKi exposed
2Y PFS PVR 86.9% vs VR 71.8%
Subgroups of TP53 & PD on cBTKi marked ⬆️PFS
Substantial ⬆️ in PFS with little added tox.
Practice changing trial in R/R #CLL
#pirtobrutinib #BRUINCLL322 #EHA2026 https://t.co/K4dAqe9QY0
👁 2.5K
❤ 43
🔁 12
🩸 MY TOP 10 TRIALS TO WATCH AT #EHA2026
🔬 MYELOID MALIGNANCIES
1️⃣ HOVON 156 / AMLSG 28-18
Gilteritinib vs Midostaurin in FLT3-mutated AML
⭐ Perhaps the most important AML readout of EHA2026.
2️⃣ SENTRY
Selinexor + Ruxolitinib in frontline myelofibrosis
⭐ Potential new https://t.co/rsh6x3ubfM
👁 2.1K
❤ 37
🔁 11
Clinical Trials14 trials with discussion
HOVON156 / PASHA
Gilteritinib vs Midostaurin · FLT3-mut NDAML (LB5005, P3)
▼
🚨 breaking news from #EHA2026 GILTERITINIB did NOT improve OS over MIDOSTAURIN IN 760-patient randomized phase 3 trial of their combinations with intensive chemo for newly diagnosed FLT3Mut #AMLsm trial
EHA Library; Jun 02 2026; 4214972
https://t.co/jSa9RgSKue
👁 6.5K
❤ 88
🔁 25
GILTERITINIB VERSUS MIDOSTAURIN IN PATIENTS WITH NEWLY DIAGNOSED FLT3-MUTATED ACUTE MYELOID LEUKEMIA ELIGIBLE FOR INTENSIVE THERAPY: RESULTS FROM THE PHASE 3 HOVON156/AMLSG28-18/PASHA TRIAL https://t.co/QDCXtWufWn #EHA26 #AML #FLT3 https://t.co/ZpvXtVpMxl
👁 860
❤ 18
🔁 8
OPTI-AML
Aza + Ven, 28- vs 14-day schedule · NDAML >=60y (Ph2, S126)
▼
Excited to head to #EHA2026 where I will present results of the much anticipated OPTI-AML study on behalf of the BEAT AML investigators @bcutd_research Master Trial ,Thurs Jun 11-see details 👇🏾. Hope to see many of you there ! In the words of ABBA seeing as we are in Stockholm. https://t.co/si0GNJ6Ict
👁 4.9K
❤ 67
🔁 10
OPTI-AML: PROSPECTIVE RANDOMIZED PHASE 2 TRIAL OF 28 VERSUS 14 DAY SCHEDULE OF VENETOCLAX AND AZACITIDINE FOR 2 CYCLES IN NEWLY DIAGNOSED GENOMICALLY AGNOSTIC ACUTE MYELOID LEUKEMIA PATIENTS ≥60 YEARS https://t.co/2Z9lgkHe8Q #EHA26 #AML #leusm https://t.co/lPDB3ADqSx
👁 456
❤ 3
🔁 1
CONGRESS | #EHA2026 | PRESENTATION
Uma Borate, Ohio State University, US, presents findings from the phase II OPTI-AML trial of 28- vs 14-day schedules of venetoclax + azacitidine for 2 cycles in patients aged ≥60 years with ND, genomically agnostic AML (N = 169).
After 2 https://t.co/jRAIHvdAMj
👁 181
❤ 4
🔁 1
I couldn’t be more proud to have @beatalleukemia lead the amazing Opti-AML trial for #BeatAML and for the amazing presentation at #EHA2026!
@bcutd_research https://t.co/qLolR1YbSw
👁 51
❤ 1
🔁 0
#EHA2026 #AML #leusm
Dr. Barote: OPTI-AML: the first prospective RCT of Ven 14d vs 28d + Aza ×2 cycles in older AML — and it reframes the whole “shorter is fine” debate.
AV14 did NOT meet non-inferiority for CR (43% vs 49% AV28; ΔCI –8% to +21%, upper bound >10%).
Key https://t.co/DyY5d2kTuV
👁 25
❤ 0
🔁 0
REVSTAR-123
Switchable allo CAR-T · CD123+ AML (LB5007, P1)
▼
Is Avencell basically Bellicum 2.0? "Switchable" Car-T, anti-CD123, albeit allogeneic #EHA2026 https://t.co/6vEXToJFf8
👁 2.4K
❤ 2
🔁 0
FIRST-IN-CLASS SWITCHABLE ALLOGENEIC CAR-T THERAPY FOR CD123+ AML – RESULTS FROM THE PHASE IA REVSTAR-123 (AVC-201-01) STUD https://t.co/FhEzvFUJiA #EHA26 #AML #CART https://t.co/y3wv6mZwDi
👁 1.8K
❤ 27
🔁 9
6. RevSTAR-123: First-in-class switchable allogeneic CD123 CAR-T demonstrated favorable safety and promising efficacy in R/R AML, achieving CR-level responses in 4/8 patients at higher dose levels without treatment-related mortality or neurotoxicity.
👁 128
❤ 0
🔁 0
KOMET-007
Ziftomenib + 7+3 induction · NPM1m/KMT2Ar NDAML (S130)
▼
Excited to be heading to #EHA2026 and to open the oral presentations session for novel #AMLsm therapies with an exciting update on #KOMET007 study combination of #Ziftomenib with 7+3 which then will be closed by my @YaleCancer colleague Nikolai Podoltsev presenting on Tuspetinib https://t.co/rOCIiy4ucz
👁 2.4K
❤ 53
🔁 5
ZIFTOMENIB COMBINED WITH INTENSIVE INDUCTION (7+3) FOR NEWLY DIAGNOSED NPM1‑M OR KMT2A-R ACUTE MYELOID LEUKEMIA (AML): LONG-TERM RESULTS FROM THE KOMET-007 TRIAL https://t.co/1q7UGo6OmK #EHA26 https://t.co/jP7ShUlbo8
👁 964
❤ 13
🔁 3
4/5 #menin_inhibitor Frontline combinations may be next emerging strategy:
7+3 + Menin inhibitor
Goal:
Morphologic CR → molecular CR → MRD negativity
Ongoing trials:
📌 KOMET-007 (PII) KOMET 017 (PIII) ziftomenib combinations)
📌 Revumenib frontline combination studies https://t.co/S7iNdRbEsp
👁 514
❤ 4
🔁 2
KOMET-007 ziftomenib + ven/aza in R/R NPM1-m AML: CRc 46%. But ven-naïve = 70% CRc, 75% MRD-neg. Ven-exposed = 24% CRc. @SAStricklandMD Personally, I'm a big fan of Menin-inh and its potential broad role in AML.
https://t.co/ur3sPgUoJu
👁 427
❤ 3
🔁 0
BRUIN CLL-322
Pirtobrutinib + Ven-Rituximab · R/R CLL/SLL (LB5001)
▼
#EHA2026 LBA
Primary results of BRUIN CLL322
FD Pirto-VenR vs VenR
80% cBTKi exposed
2Y PFS PVR 86.9% vs VR 71.8%
Subgroups of TP53 & PD on cBTKi marked ⬆️PFS
Substantial ⬆️ in PFS with little added tox.
Practice changing trial in R/R #CLL
#pirtobrutinib #BRUINCLL322 #EHA2026 https://t.co/K4dAqe9QY0
👁 2.5K
❤ 43
🔁 12
Oral presentation at #EHA2026 — June 14, 9:15–9:30, Nobel Hall:
BRUIN CLL-322 phase 3 trial in previously treated CLL/SLL (fixed-duration noncovalent BTK inhibitor + venetoclax–rituximab vs venetoclax–rituximab).
Details in the program: https://t.co/9B3wkfeiZv
#CLL https://t.co/4fQJp7haGv
👁 92
❤ 0
🔁 0
SAVE
Revumenib + Ven + Decitabine/Cedazuridine · R/R AML
▼
#EHA2026 simultaneous publication by @ghayasissa et al:
The All-Oral Combination of Revumenib, Decitabine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia (SAVE)
Read the full article: https://t.co/d4LiPVj7Mu https://t.co/5Lj1NuuUZR
👁 941
❤ 7
🔁 5
CONGRESS | #EHA2026 | POSTER
Branko Cuglievan, University of Texas MD Anderson Cancer Center, US, shares findings from a phase I/II study of an all-oral combination of revumenib + decitabine/cedazuridine + venetoclax in patients with R/R AML (N = 42).
The ORR was 88%, with a https://t.co/EHW9VIVUIp
👁 166
❤ 2
🔁 1
LD-VenEx
Aza + reduced-duration Ven · de novo/secondary/R/R AML (Nordic, S129)
▼
NCT03471260
Ivosidenib + Aza + Ven · IDH1-mut AML (Ph1b/2, S127)
▼
Swing by our poster PF565 on Gilteritinib+Ven or Ivosidenib+Ven based treatments of FLT3/IDH1m AML from 18.45 today🩸
@EHA_Hematology #eha2026
@VU_LT https://t.co/amrgZqp23Y
👁 171
❤ 9
🔁 0
CONGRESS | #EHA2026 | POSTER
Vanessa Kennedy, Stanford University, US, shares real-world treatment patterns and outcomes with ivosidenib in patients with R/R, IDH1-mutated AML (N = 24).
IC was the most commonly received treatment prior to ivosidenib, with 50% of patients https://t.co/YMJTc9gnSZ
👁 138
❤ 2
🔁 0
Quizartinib + Dec + Ven
FLT3-ITD AML triplet (PF509 / PS1621)
▼
SNDX-5613-0708
Revumenib + intensive chemo · newly diagnosed AML (PF489)
▼
AUGMENT-101
Revumenib · KMT2Ar/NPM1m acute leukemia
▼
ASC4FIRST
Asciminib · newly diagnosed CML
▼
📌 ASC4FIRST – T. Hughes
After 3yrs, asciminib demonstrate superior molecular responses together with an excellent safety profile in newly diagnosed CML-CP.
These long-term data further support asciminib as a frontline standard of care.
#CML #EHA2026 #HEMandNET #HematoEnR https://t.co/u1lN4KSasE
👁 63
❤ 1
🔁 1
📢 #EHA2026 update: first iCMLf CML session summary now available.
Highlights:
🔹 3-year ASC4FIRST results with asciminib
🔹 Second TFR attempts (ReStop & NAUT)
🔹 Asciminib combination strategies
🔹 Early results with ELVN-001
Read the full summary here: https://t.co/YxSIX0OaoM https://t.co/23OOew426m
👁 22
❤ 0
🔁 0
NX-5948-301
Bexobrutideg (BTK degrader) · R/R CLL
▼
Sonrotoclax + Zanubrutinib
All-oral 1L CLL/SLL — uMRD >90% (S145)
▼
MDS / MPN & Other Heme178 tweets captured
I look forward to this very important presentation in #EHA2026 about value of transplant in TP53 mutated #MDSsm and #AMLsm. The results clearly indicate a tail at end of curve and around 20% 23-year OS even among biallelic TP53mut patients, and especially in those with lower https://t.co/AmGaqgHQsa
👁 6.5K
❤ 85
🔁 26
IMPACT OF RUSFERTIDE ON POLYCYTHEMIA VERA (PV)-RELATED SYMPTOMS AND PATIENT-REPORTED OUTCOME-RELATED ITEMS IN THE RANDOMIZED, DOUBLE-BLIND PHASE 3 VERIFY STUDY https://t.co/uLdWLs3be1 #mpnsm #EHA26 https://t.co/Dx4RiQPuev
👁 1.9K
❤ 15
🔁 5
Just published in Nature Reviews Disease Primers during #EHA26
Chronic GvHD remains one of the greatest unmet needs after allogeneic transplantation.
The mission is no longer just to help patients survive transplantation, but to help them live well after it. @TheIACH https://t.co/fGk5atXBwz
👁 1.2K
❤ 42
🔁 16
Only 1 more week until #EHA2026 in Stockholm! We look forward to exploring the latest advancements and cutting-edge developments in #hematology. Have you mapped out your conference agenda yet? https://t.co/gUUe9v8zOe
👁 1.1K
❤ 2
🔁 0
looking forward to presenting our data, discussing cutting-edge science, and meeting colleagues & friends at the European Hematology Association 2026 Congress in Stockholm! 🥰🤓🙌
#EHA2026 @EHA_Hematology https://t.co/0WqwJWzDUJ
👁 1.0K
❤ 21
🔁 0
👏👏👏Lovely to sit in the front row cheering on our friend & mentor & close collaborator Prof .@harrisoncn1 giving her @EHA_Hematology career achievement award 🥇 speech at #EHA26 #EHA2026 ! A truly special moment for our MPN field! #MPNSM | @mpdrc @jjkiladjian @FlorianHeidel https://t.co/Ga8ko0bDsG
👁 926
❤ 39
🔁 5
Clinical Trials7 trials with discussion
VERIFY
Rusfertide · polycythemia vera PRO/symptoms (Ph3, PF898)
▼
IMPACT OF RUSFERTIDE ON POLYCYTHEMIA VERA (PV)-RELATED SYMPTOMS AND PATIENT-REPORTED OUTCOME-RELATED ITEMS IN THE RANDOMIZED, DOUBLE-BLIND PHASE 3 VERIFY STUDY https://t.co/uLdWLs3be1 #mpnsm #EHA26 https://t.co/Dx4RiQPuev
👁 1.9K
❤ 15
🔁 5
CONGRESS | #EHA2026 | POSTER
Naveen Pemmaraju presents long-term results concerning thromboembolic and progression events in patients who enrolled in the phase II REVIVE trial (n = 70) and transitioned to the phase III open-label THRIVE trial (n = 46), evaluating rusfertide in https://t.co/lZCwTyU5fk
👁 347
❤ 7
🔁 2
Excellent talk by Dr. Francesca Palandri on ET/PV at #EHA2026 #mpnsm #EHA26
Key takeaways:
Hydroxyurea remains the main 1L cytoreductive therapy, but care is increasingly individualized.
Emerging directions:
1. Hepcidin modulation in PV, rusfertide and TMPRSS6 inhibitors
2. https://t.co/mBBogtf4az
👁 204
❤ 6
🔁 2
MATTERHORN
Roxadustat · LR-MDS anemia / high transfusion burden (PF668)
▼
PALOMA
CPX-351 (Vyxeos) vs SoC bridge to alloHCT · HR-MDS/oligoblastic AML (S170)
▼
CPX-351 VERSUS STANDARD OF CARE AS BRIDGING TO ALLOHCT IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC NEOPLASMS OR OLIGOBLASTIC ACUTE MYELOID LEUKEMIA: RESULTS OF THE RANDOMIZED PHASE 2 PALOMA STUDY..
EHA Library; Jun 12 2026; 4206724
https://t.co/50isLuRjrT #EHA26 #mds https://t.co/wUoTVmd6tZ
👁 1.2K
❤ 16
🔁 3
Paloma study: CPX-351 vs.CCR before allo for HR-MDS: Jury is still out...#MDSsm #EHA2026 https://t.co/3y735eOc0d
👁 58
❤ 1
🔁 0
#Paloma study in #HR_MDS. CPX351 had better EFS but similar OS to 7+3 or AZA. Interim analysis. #EHA2026 https://t.co/lMY4FGm516
👁 43
❤ 0
🔁 0
EPO-PRETAR
Epoetin alfa early vs delayed · LR non-TD MDS (Ph3, S171)
▼
EARLY VERSUS DELAYED ESA IN LOWER-RISK NON -TRANSFUSION-DEPENDENT MDS: FINAL PHASE III EPO-PRETAR RESULTS ON TRANSFUSION DEPENDENCE AND ERYTHROID RESPONSE .. by Prof. Sophie Park
EHA Library; Jun 12 2026; 4206725
https://t.co/gNtcPM631F #EHA26 #MDS https://t.co/636WszbFTd
👁 803
❤ 11
🔁 2
#EHA2026 #EHA26 #mdssm #poster_presentation
Interesting translational data from the EPO-PRETAR trial presented at #EHA2026 exploring predictors of ESA response in lower-risk MDS.
Early ESA response in LR-MDS appears linked to adaptive immune activation, especially CD4/CD8 https://t.co/F78UpTJJMs
👁 178
❤ 4
🔁 1
MAXILUS
Luspatercept at max dose · transfusion-dependent LR-MDS (S173)
▼
SENTRY
Selinexor + Ruxolitinib · JAKi-naive myelofibrosis (LB5002, P3)
▼
MANIFEST-2
Pelabresib + Ruxolitinib · myelofibrosis
▼
Street Signals
Finance & Market Buzz
$cashtag commentary from credible biotech analysts and journalists on EHA 2026 readouts. Tickers in play:
$LEGN$ELVN$MRK$ABBV$RHHBY$COGT$SNDX$JNJ
New $ELVN data at #EHA26
Enliven Therapeutics’ leukemia drug shows promise in new study https://t.co/lTp83y4Srz $MRK
👁 17.4K
❤ 16
🔁 3
$LEGN in vivo CD19 x CD20 Car-T LB2501: 0% ORR at dose level 1, 100% ORR (6/6), 83% CR rate (5/6) at dose level 2 #EHA2026 https://t.co/AjbY4Ja75a
👁 7.3K
❤ 20
🔁 4
🇸🇪 I’m going to be in Sweden all next week, why not. Will be visiting the biotech town of Lund on Tuesday and then up to Stockholm for #EHA2026 Thursday - Saturday.
👁 6.5K
❤ 50
🔁 0
A notable hematology breakthru: all-oral regimen of Inqovi (oral decitabine-cedazuridine by Taiho Onc) & Venclexta (venetoclax by $ABBV $RHHBY) may allow newly diagnosed acute myeloid leukemia patients age 75+ 2b treated @ home w/ 2 daily pills instead of injections #AML #EHA26. https://t.co/CGk7IKEaPd
👁 4.7K
❤ 20
🔁 6
$COGT Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at #EHA26
https://t.co/1g1bLf76uZ
👁 4.6K
❤ 4
🔁 0
$SNDX - seems we've been underestimating the chemo combination for Revuforj in 1st line AML #EHA2026 https://t.co/r6DgwXtYaw
👁 3.1K
❤ 24
🔁 3
$LEGN detailing an ORR of 100% (6/6) at DL2 with LB2501 (CD19/20-targeting in vivo Car-T) #EHA2026 https://t.co/BZjjThUgem https://t.co/Lxd3fNXZCl
👁 2.1K
❤ 8
🔁 5
J&J details data backing Imaavy's bid in warm autoimmune haemolytic anaemia $JNJ #EHA2026 https://t.co/BUloAdgAS3
👁 367
❤ 1
🔁 0
News & Publications
Major Media Coverage at EHA 2026
Key stories, publications, and press coverage from the EHA Congress — curated from major oncology media and the hematology newsroom.
Press Release
Kura/Kyowa Kirin: Ziftomenib + 7+3 (KOMET-007) Posts 96% CRc in Frontline NPM1-m AML
Long-term KOMET-007 data in 99 newly diagnosed NPM1-m or KMT2A-r AML patients: composite CR 96% (NPM1-m) and 90% (KMT2A-r), MRD-negativity 85%/82%, and 1-year OS of 94% (NPM1-m), outpacing historical 7+3 benchmarks.
Press ReleaseAbbVie: CLL14 Nine-Year Data — Fixed-Duration Venetoclax + Obinutuzumab in 1L CLL
Final Phase 3 CLL14 analysis at 9.2-year median follow-up: median PFS 6.4 vs 3.2 years (HR 0.50) and median time-to-next-treatment of 7.6 years for one year of fixed-duration venetoclax-obinutuzumab vs chlorambucil-obinutuzumab in previously untreated, unfit CLL.
Press ReleaseKaryopharm: SENTRY — Selinexor + Ruxolitinib Nearly Doubles SVR35 in Frontline Myelofibrosis
Phase 3 SENTRY (LB5002): selinexor + ruxolitinib achieved a week-24 SVR35 of 49.8% vs 28.0% with ruxolitinib alone in JAKi-naive myelofibrosis, with an early OS signal — though the co-primary total-symptom-score endpoint was not met.
Media CoveragefrontMIND: Tafasitamab + Lenalidomide + R-CHOP Cuts Progression Risk 25% in 1L High-Risk DLBCL
Phase 3 frontMIND met its primary endpoint: PFS HR 0.75 (P=0.019) vs R-CHOP, with 24-month PFS 72.7% vs 62.2%. Benefit held across cell-of-origin subtypes of DLBCL and HGBL — a potential new 1L standard for high-risk aggressive B-cell lymphoma.
Press ReleaseSyndax: Revuforj (Revumenib) Shows Activity Across Acute Leukemia Subtypes — SAVE Trial 88% ORR
12 abstracts on the first-in-class menin inhibitor at EHA 2026. Ph 2 SAVE (revumenib + venetoclax + decitabine/cedazuridine) showed 88% ORR and 68% MRD-negativity in R/R NPM1m/KMT2Ar/NUP98r AML; frontline combo reached 97% CRc.
Press ReleaseAbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026
21 oral and poster presentations spanning MM, FL, CLL, DLBCL, AML and AL amyloidosis — featuring EPKINLY (epcoritamab), VENCLEXTA (venetoclax), investigational BCMA bispecific etentamig (ABBV-383), and pivekimab sunirine.
Press ReleaseBeOne: Landmark Phase 3 BRUKINSA (Zanubrutinib) Data in CLL Patients Aged 80+
One of the largest datasets of older treatment-naive CLL patients — sustained benefit with BRUKINSA after nearly 6.5 years of follow-up, reinforcing its role as the foundational BTK inhibitor (only BTKi superior to ibrutinib in a Ph 3 trial).
Press ReleaseNurix: Updated Phase 1a/b Data for BTK Degrader Bexobrutideg (NX-5948) in R/R CLL/SLL
Durable responses with the CNS-penetrant oral BTK degrader across difficult-to-treat CLL subgroups — including high-risk features, BTK resistance mutations, and CNS involvement — supporting a broad Phase 3 monotherapy program.
Press ReleaseBlossomHill: First Clinical Data for CLK Inhibitor BH-30236 in R/R AML / HR-MDS
Initial dose-escalation data from the first-in-human Phase 1/1b of BH-30236, an oral macrocyclic CDC-like kinase (CLK) inhibitor that modulates aberrant mRNA splicing, in relapsed/refractory AML and higher-risk MDS.
Media CoverageEHA 2026 | Top Abstracts: What's Hot in Lymphoma and CLL
Steering-committee picks for Stockholm: BRUIN CLL-322 (pirtobrutinib + ven-rituximab), final CLL14 (ven-obinutuzumab), sonrotoclax + zanubrutinib frontline (>90% uMRD), and first-in-human in vivo dual CD19/CD20 CAR-T (LB2501).
Media CoverageAn Early Look at EHA 2026: 10 Key Studies Heading to Stockholm
A sneak peek at the heme-onc agenda: CLL triplets, frontline menin inhibition in AML, earlier myeloma bispecifics, and post-JAK myelofibrosis combinations.
Media CoveragePreviewing Key Myeloma Presentations to Watch at EHA 2026
Joshua Richter, MD previews the most anticipated multiple myeloma presentations ahead of the 2026 EHA Congress — bispecifics moving earlier, CAR-T subgroup analyses, and smoldering myeloma data.
Media CoverageEHA 2026: Hematology Comes to Stockholm With Patients at the Forefront
The 31st EHA Congress (June 11–14, Stockholmsmässan) convenes the global hematology community for four days of plenary and late-breaking science across myeloma, leukemia, lymphoma, and other blood cancers.
Media CoverageBostonGene: AI Models and Biomarker Frameworks for Blood Cancers at EHA 2026
Six abstracts (with MSK, Weill Cornell, Miami, MD Anderson) applying predictive multiomics to risk-stratify newly diagnosed myeloma, define CAR-T resistance phenotypes, and optimize frontline decisions in blood cancers.
Media CoverageEHA 2026 | Top AML Abstracts: REVSTAR-123, HOVON/PASHA, KOMET-007
AML Hub Steering Committee picks: switchable allo CD123 CAR-T (REVSTAR-123, Wermke), gilteritinib vs midostaurin in FLT3-mut NDAML (HOVON156/AMLSG28-18/PASHA, Raaijmakers), and long-term ziftomenib + 7+3 from KOMET-007 (Zeidan).
Media CoverageEHA 2026 | Top Myeloma Abstracts: SUCCESSOR-2, DREAMM-7, CAMMA-2
Late-breaker MeziKd vs Kd in RRMM (SUCCESSOR-2 / LB5004, Dimopoulos), 4-year DREAMM-7 (belantamab) update, and cevostamab after prior BCMA CAR-T (CAMMA-2, Kumar) headline the plasma-cell program.
Media CoverageMPN & AML Preview: Type II JAK Inhibitors and Post-JAK Myelofibrosis Combos
Experts preview key MPN/AML data for Stockholm — including the Phase 3 SENTRY trial of selinexor + ruxolitinib in JAK-inhibitor-naive myelofibrosis (SVR35 ~50% vs 28%) and emerging Type II JAK inhibitor data.